EU’s AMR Transferable Exclusivity Voucher Plan 'Not Fit For Purpose'
A European public health NGO has disputed the suggestion that a transferable exclusivity extension is the answer to the lack of innovative antimicrobial drugs in company pipelines.
You may also be interested in...
A new study shows that transferable exclusivity extension vouchers are the best way of incentivizing antibiotic development in Europe. However, investors caution that other strategies must also be considered.
At a recent webinar payers and health technology appraisal bodies gave further details on what they want included and left out of the European Commission’s overhaul of the EU pharmaceutical legislation. However, speakers voiced some concerns about whether their demands will be met.
The director-general of the European Commission’s recently-formed Health Emergency Response Authority addressed delegates at the off-patent association Medicines for Europe’s 2022 annual conference, noting that HERA was preparing a report for post-summer as it assessed its priorities.